There are 807 resources available
337P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster viewing 05.
338P - Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Presenter: Joe Wei
Session: Poster viewing 05.
339P - Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
Presenter: Charlotte McKay
Session: Poster viewing 05.
341P - Cost-effectiveness analysis of first-line atezolizumab for patients with stage IV non-small cell lung cancer whose tumours have a high-programmed death ligand 1 expression in Thailand
Presenter: Kankamon Kittrongsiri
Session: Poster viewing 05.
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Presenter: Herdee Gloriane Luna
Session: Poster viewing 05.
343P - Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Presenter: Harshitha N.J
Session: Poster viewing 05.
344P - Loco-regional radiotherapy (RT) in M1a non-small cell lung cancer (NSCLC) downstaged with chemotherapy (CT)
Presenter: Hegde Adarsh Gajanan
Session: Poster viewing 05.
345P - First-line gemcitabine-platinum chemotherapy in relapsed or metastatic pulmonary lymphoepithelioma-like carcinoma: A tertiary centre experience
Presenter: Gavin Tin Chun Cheung
Session: Poster viewing 05.
346P - The safety and efficacy of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective study
Presenter: Huiying Li
Session: Poster viewing 05.